Oncocyte raises $29.1M equity; Bio-Rad invests; funds transplant assay to FDA clearance

Insight Molecular Diagnostics Inc.

Gross proceeds of $29.1M from registered direct ($7.4M) and PIPE ($21.7M) offerings at $2.05/share.
Five largest shareholders led round, including strategic partner Bio-Rad Laboratories (NYSE: BIO).
Proceeds expected to fully fund FDA IVD clearance and commercial launch of proprietary transplant assay.
Terminated at-the-market Sales Agreement with Needham; $1.8M previously sold under it.

item 1.01 item 1.02 item 3.02 item 7.01 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.